Loading...
XKRX
069620
Market cap1.11bUSD
Apr 30, Last price  
138,000.00KRW
1D
0.88%
Jan 2017
100.87%
Name

Daewoong Pharma

Chart & Performance

D1W1MN
P/E
64.20
P/S
1.12
EPS
2,149.65
Div Yield, %
—
Shrs. gr., 5y
2.20%
Rev. gr., 5y
5.02%
Revenues
1.42t
+3.44%
400,443,393,000484,346,075,000548,326,626,000613,750,337,000509,993,136,000710,547,146,300669,013,832,880682,508,015,670735,889,423,940839,686,478,170883,920,424,600960,307,423,0401,031,427,425,5301,113,425,920,8801,055,423,690,0001,152,975,698,1701,280,091,851,0101,375,328,744,8771,422,683,296,380
Net income
24.73b
-77.82%
48,523,054,00058,948,245,00032,930,963,00049,467,008,00017,562,830,00050,185,946,00034,079,293,66058,399,564,79031,544,474,83042,930,060,24026,969,821,26031,580,584,390-15,151,848,39022,005,927,02024,148,065,67024,505,735,56042,239,518,340111,501,799,11024,734,510,690
CFO
51.49b
-61.16%
48,962,960,00025,810,021,00031,326,248,00093,907,855,00020,110,498,00078,822,880,64045,023,829,91054,157,051,36025,945,213,40035,887,836,00015,377,371,370103,938,172,74047,499,563,37057,600,275,950100,981,257,11039,994,278,510118,214,603,330132,568,693,21051,492,294,010
Dividend
Dec 27, 2023600 KRW/sh
Earnings
Aug 07, 2025

Profile

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
URL
https://www.daewoong.co.kr/kr/main/index
IPO date
Nov 01, 2002
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,422,683,296
3.44%
1,375,328,745
7.44%
1,280,091,851
11.03%
Cost of revenue
1,127,991,735
1,085,146,292
1,050,152,118
Unusual Expense (Income)
NOPBT
294,691,562
290,182,453
229,939,733
NOPBT Margin
20.71%
21.10%
17.96%
Operating Taxes
33,203,972
129,444
(833,512)
Tax Rate
11.27%
0.04%
NOPAT
261,487,590
290,053,009
230,773,245
Net income
24,734,511
-77.82%
111,501,799
163.98%
42,239,518
72.37%
Dividends
(7,740,654)
(6,641,525)
(6,641,525)
Dividend yield
0.53%
0.50%
0.38%
Proceeds from repurchase of equity
49,889,893
BB yield
-3.74%
Debt
Debt current
323,497,286
370,385,455
234,855,580
Long-term debt
329,027,934
69,457,523
220,053,752
Deferred revenue
33,650,213
33,527,566
39,184,776
Other long-term liabilities
57,644,885
30,973,813
94,192,954
Net debt
368,871,865
9,774,402
205,623,113
Cash flow
Cash from operating activities
51,492,294
132,568,693
118,214,603
CAPEX
(155,145,001)
(109,337,876)
(113,308,833)
Cash from investing activities
(265,450,884)
(165,620,550)
(106,871,719)
Cash from financing activities
200,621,153
39,218,430
15,516,597
FCF
97,595,397
187,656,397
162,882,525
Balance
Cash
116,347,424
137,684,957
140,650,847
Long term investments
167,305,932
292,383,619
108,635,372
Excess cash
212,519,191
361,302,139
185,281,627
Stockholders' equity
796,985,767
821,779,528
1,131,167,659
Invested Capital
1,322,664,826
1,148,063,859
1,126,783,874
ROIC
21.17%
25.50%
21.09%
ROCE
17.64%
19.16%
17.47%
EV
Common stock shares outstanding
11,505
11,424
11,069
Price
126,400.00
8.22%
116,800.00
-26.31%
158,500.00
7.09%
Market cap
1,454,259,050
8.99%
1,334,365,832
-23.94%
1,754,469,468
7.72%
EV
1,955,475,758
1,489,118,018
2,093,298,206
EBITDA
343,669,958
332,883,130
269,634,397
EV/EBITDA
5.69
4.47
7.76
Interest
6,986,368
13,149,680
8,405,545
Interest/NOPBT
2.37%
4.53%
3.66%